Posted by Michael Wonder on 05 Jun 2019
Paying for CAR-T therapy amidst limited health system resources
3 June 2019 - CAR-T is paving a new path toward achieving access and reimbursement within limited health-system resources. How do we align incentives of US health systems to reward payments for CAR-T therapy that achieve fair value?
On top of the cost-effectiveness evidence, but arguably a component of the larger domain of value, Lin et al conclude that if CAR-T were to reach all indicated US patients with DLBCL, the overall spending on all patients with non-Hodgkin lymphoma would increase by around $2 billion per year (a 68% increase from spending in 2013).
